Abbott Laboratories (ABT) stock
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3034% above fair value
$103.87−0.61 (-0.58%)
Close on Nov 19, 2026Market cap $179.74BP/E 33.4Yield 2.31%
Abbott Laboratories free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Abbott Laboratories's free cash flow for the twelve months ending Jun 30, 2026 was $7.82B, up 15.5% year over year. For fiscal 2025 it was $7.40B, up 16.4% from the year before. Over ten years it grew 14.8% a year on average. The highest annual figure on record is $8.65B in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.40B | +16.4% |
| FY2024 | Dec 31, 2024 | $6.35B | +25.5% |
| FY2023 | Dec 31, 2023 | $5.06B | -35.2% |
| FY2022 | Dec 31, 2022 | $7.80B | -9.8% |
| FY2021 | Dec 31, 2021 | $8.65B | +51.1% |
| FY2020 | Dec 31, 2020 | $5.72B | +27.3% |
| FY2019 | Dec 31, 2019 | $4.50B | -8.3% |
| FY2018 | Dec 31, 2018 | $4.91B | +10.6% |
| FY2017 | Dec 31, 2017 | $4.44B | +113.0% |
| FY2016 | Dec 31, 2016 | $2.08B | +12.2% |
| FY2015 | Dec 31, 2015 | $1.86B | -28.6% |
| FY2014 | Dec 31, 2014 | $2.60B | +19.2% |
| FY2013 | Dec 31, 2013 | $2.18B | -71.0% |
| FY2012 | Dec 31, 2012 | $7.52B | +0.5% |
| FY2011 | Dec 31, 2011 | $7.48B | -3.1% |
| FY2010 | Dec 31, 2010 | $7.72B | +24.8% |
| FY2009 | Dec 31, 2009 | $6.19B | +8.4% |
| FY2008 | Dec 31, 2008 | $5.71B | +61.8% |
| FY2007 | Dec 31, 2007 | $3.53B | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.99B | +28.9% |
| Q1 FY2026 | Mar 31, 2026 | $916.00M | -1.8% |
| Q4 FY2025 | Dec 31, 2025 | $2.63B | +22.3% |
| Q3 FY2025 | Sep 30, 2025 | $2.29B | +6.6% |
| Q2 FY2025 | Jun 30, 2025 | $1.55B | +8.3% |
| Q1 FY2025 | Mar 31, 2025 | $933.00M | +48.8% |
| Q4 FY2024 | Dec 31, 2024 | $2.15B | -5.9% |
| Q3 FY2024 | Sep 30, 2024 | $2.15B | +63.2% |
| Q2 FY2024 | Jun 30, 2024 | $1.43B | +105.0% |
| Q1 FY2024 | Mar 31, 2024 | $627.00M | -17.8% |
| Q4 FY2023 | Dec 31, 2023 | $2.28B | +33.0% |
| Q3 FY2023 | Sep 30, 2023 | $1.32B | -43.1% |
| Q2 FY2023 | Jun 30, 2023 | $696.00M | -65.7% |
| Q1 FY2023 | Mar 31, 2023 | $763.00M | -56.3% |
| Q4 FY2022 | Dec 31, 2022 | $1.72B | -30.0% |
| Q3 FY2022 | Sep 30, 2022 | $2.31B | +3.3% |
| Q2 FY2022 | Jun 30, 2022 | $2.03B | +18.4% |
| Q1 FY2022 | Mar 31, 2022 | $1.74B | -22.1% |
| Q4 FY2021 | Dec 31, 2021 | $2.45B | -21.4% |
| Q3 FY2021 | Sep 30, 2021 | $2.24B | +42.7% |
| Q2 FY2021 | Jun 30, 2021 | $1.72B | +152.2% |
| Q1 FY2021 | Mar 31, 2021 | $2.24B | +531.0% |
| Q4 FY2020 | Dec 31, 2020 | $3.12B | +57.4% |
| Q3 FY2020 | Sep 30, 2020 | $1.57B | +1.5% |
| Q2 FY2020 | Jun 30, 2020 | $680.00M | +14.9% |
| Q1 FY2020 | Mar 31, 2020 | $355.00M | -5.8% |
| Q4 FY2019 | Dec 31, 2019 | $1.98B | +52.7% |
| Q3 FY2019 | Sep 30, 2019 | $1.55B | -15.4% |
| Q2 FY2019 | Jun 30, 2019 | $592.00M | -37.4% |
| Q1 FY2019 | Mar 31, 2019 | $377.00M | -54.7% |
| Q4 FY2018 | Dec 31, 2018 | $1.30B | +0.2% |
| Q3 FY2018 | Sep 30, 2018 | $1.83B | +5.0% |
| Q2 FY2018 | Jun 30, 2018 | $946.00M | -13.7% |
| Q1 FY2018 | Mar 31, 2018 | $833.00M | +175.8% |
| Q4 FY2017 | Dec 31, 2017 | $1.30B | +52.2% |
| Q3 FY2017 | Sep 30, 2017 | $1.74B | +92.5% |
| Q2 FY2017 | Jun 30, 2017 | $1.10B | – |
| Q1 FY2017 | Mar 31, 2017 | $302.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $851.00M | – |
| Q3 FY2016 | Sep 30, 2016 | $905.00M | – |
See a number that looks wrong?